ID
44154
Descripción
NCT02641314 Phase 2 Trial of Metronomic Treatment in Children and Adolescents With Recurrent or Progressive Neuroblastoma (NB). The study investigates the tolerance and the efficacy of a new combination of five drugs consisting of propranolol (antiangiogenetic, anti-neuroblastic), Celecoxib (modulating immune response, ant-neuroblastic), cyclophosphamide (antiangiogenetic, anti-neuroblastic), etoposide (antiangiogenetic, anti-neuroblastic), and vinblastin (antiangiogenetic, anti-neuroblastic). Vinblastin is scheduled every 14 days intravenously, all other drugs are applied daily throughout 365 days (except etoposide for 4x3 weeks). The efficacies of each of the drugs have been demonstrated in vitro and in vivo in animal studies. All drugs have been used in children for other conditions. From those experiences low toxicities and a favorable Quality of life are expected. Prof. Dr. Frank Berthold Abt. für Kinderonkologie und –hämatologie Zentrum für Kinder- und Jugendmedizin Universität zu Köln
Palabras clave
Versiones (5)
- 26/12/17 26/12/17 -
- 27/12/17 27/12/17 -
- 15/3/21 15/3/21 - Dr. rer. medic Philipp Neuhaus
- 13/4/21 13/4/21 - Dr. rer. medic Philipp Neuhaus
- 20/9/21 20/9/21 -
Titular de derechos de autor
Universität zu Köln
Subido en
20 de septiembre de 2021
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma (METRO-NB2012) NCT02641314
Registration
- StudyEvent: Subject Protocol
- Registration
- Medical history
- Baseline
- Therapy and toxicity cycle 1-3
- Therapy and toxicity cycle 4-6
- Therapy and toxicity cycle 7-9
- Therapy and toxicity cycle 10-13
- Therapy and toxicity cycle > 13
- Reference
- Study relevant visits
- Therapeutic response
- End of therapy
- Relapse
- Second malignancy
- Death
- Follow up
Descripción
Einschlusskriterien
Descripción
Rezidiv oder Progression eines Hochrisikoneuroblastoms (nach INSS und GPOH-Kriterien) unabhängig von der Anzahl vorausgehender Rezidive/Progressionen?
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0027819
Descripción
Age
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0001779
Descripción
Measurable or evaluable disease
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C1513041
Descripción
Minimal interval between start of trial medication and preceding anti-cancer treatment
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C1272706
Descripción
Life expectancy
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0023671
Descripción
Good to moderate general condition
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C1142435
Descripción
No serious infection
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C0009450
- UMLS CUI [1,2]
- C0205404
Descripción
Spontaneous recovering blood counts
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0005771
Descripción
Follow-up period
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C1522577
Descripción
Written informed consent
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0021430
Descripción
Ausschlusskriterien
Descripción
Minimal residual disease
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C1511791
Descripción
Patients unable to swallow trial medication
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C3839225
Descripción
Concomitant anti-cancer treatment
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C2348568
Descripción
Antihypertensive drugs
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0003364
Descripción
Hypersensitivity to medication
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C0020517
- UMLS CUI [1,2]
- C0304229
Descripción
Severe medical or psychosocial conditions preventing trial participate
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0009488
Descripción
Peripheral neuropathy
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0031117
Descripción
Cardiac arrhythmias
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0003811
Descripción
Bronchial asthma
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0004096
Descripción
Diabetes mellitus
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0011849
Descripción
Low blood pressure
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0020649
Descripción
History of gastrointestinal ulcer or perforation
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0030920
- UMLS CUI [2]
- C0151664
Descripción
Known active hepatitis B virus (HBV), hepatitis C (HBC) virus or human immunodeficiency virus (HIV) infection
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0019682
- UMLS CUI [2]
- C0019163
- UMLS CUI [3]
- C0220847
Descripción
Concomitant participation in other clinical trials
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C2348568
Descripción
Pregnancy, lactation
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0032961
- UMLS CUI [2]
- C0006147
Descripción
Sexually active patients not willing to use highly effective contraception
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0700589
Descripción
Studieneinschluss
Alias
- UMLS CUI-1
- C1512693
- UMLS CUI-2
- C2348563
Descripción
Informed Consent
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0021430
Descripción
Comments
Tipo de datos
text
Alias
- UMLS CUI [1]
- C0947611
Descripción
Date
Tipo de datos
date
Alias
- UMLS CUI [1]
- C0011008
Descripción
Investigator name
Tipo de datos
text
Alias
- UMLS CUI [1]
- C2826892
Descripción
Investigator signature
Tipo de datos
text
Alias
- UMLS CUI [1]
- C2346576
Similar models
Registration
- StudyEvent: Subject Protocol
- Registration
- Medical history
- Baseline
- Therapy and toxicity cycle 1-3
- Therapy and toxicity cycle 4-6
- Therapy and toxicity cycle 7-9
- Therapy and toxicity cycle 10-13
- Therapy and toxicity cycle > 13
- Reference
- Study relevant visits
- Therapeutic response
- End of therapy
- Relapse
- Second malignancy
- Death
- Follow up
(Comment:de)
(Comment:de)
C0205404 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,2])
C0151664 (UMLS CUI [2])
C0019163 (UMLS CUI [2])
C0220847 (UMLS CUI [3])
C0006147 (UMLS CUI [2])
Sin comentarios